3003新葡的京集团
Other Affiliated Sites
Techdow Pharma China
Techdow Pharma UK
Techdow Pharma Poland
Techdow Pharma Italy
Techdow Pharma Spain
Techdow Pharma Germany
Techdow Pharma US
Cytovance Biologics
SPL
Simplified Chinese
Traditional Chinese
About Hepalink
Group Profile
Corporate Philosophy
Milestones
Leadership Team
Scientific Advisory Board
Our Businesses
Heparin Business
Global Industrial Chain
Global Heparin Injections Business
Product Profile
CDMO Services
Innovative Drugs
Global Manufacturing
Company News
Investor Relations
Corporate Governance
Disclosures
Stock Information
IR Events
IR Contact
Join Us
Career Development
Job Opportunities
Campus Recruitment
Contact Us
Create Value for Investors Through
Safe and Stable Operations
Corporate Governance
Disclosures
Stock Information
IR Events
IR Contact
Disclosures
A-Share Information
H-Share Information
Financial Reports
Announcements
2011.12.21
华英有限责任公司关于《深圳市3003新葡的京集团药业股份有限公司期权激励计划(草案)》之独...
2011.12.21
第二届监事会第九次会议决议公告
2011.12.21
期权激励计划激励对象名单
2011.12.20
停牌公告
2011.12.17
关于更换保荐代表人的公告
2011.12.01
关于投资设立合资企业进展的公告
2011.12.01
关于公司高级管理人员辞职的公告
2011.11.03
关于控股子公司完成增资工商变更登记的公告
2011.11.03
关于向控股子公司提供委托贷款的进展公告
2011.10.19
中国建银投资有限责任公司关于公司有关委托贷款事项的核查意见
第一页
上一页
138
139
140
141
142
下一页
最后一页
About Hepalink
Group Profile
Corporate Philosophy
Milestones
Leadership Team
Scientific Advisory Board
Our Businesses
Heparin Business
CDMO Services
Innovative Drugs
Global Manufacturing
Company News
Investor Relations
Corporate Governance
Disclosures
Stock Information
IR Events
IR Contact
Join Us
Career Development
Job Opportunities
Campus Recruitment
Contact Us
Official WeChat Account
Legal Statement
·
Environmental Disclosure
Copyright © 2024 Hepalink Group. All Rights Reserved.